Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geneart has reported that the US Patent and Trademark Office has awarded the company two patents that protect the use of specific custom-designed HIV gene sequences for the development as therapeutics or vaccines.
Subscribe to our email newsletter
The patent-protected gene sequences have been tested as HIV vaccine candidates on 40 test persons by the EuroVacc Foundation in a Phase I clinical trial. In the trial, the prophylactic vaccination proved to be safe and well tolerated, and it triggered a strong and lasting immune response in 90 % of the vaccinated test persons in London and Lausanne. As the licensor, Geneart provided the patented gene sequences (structural design) for the tested vaccines.
The synthetic genes were custom-designed by the scientists at Geneart and the University of Regensburg. These genes serve as the basis for the vaccine candidates, which are used in the so-called ‘prime boost’ procedure as naked DNA (DNA-HIV-C), and with a genetically modified small pox vaccine (NYVAC-HIV-C) as a carrier system.